Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1. Its clinical program also comprises MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to solid tumors. In addition, the company is developing preclinical product candidates for various solid tumor indications. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-441-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$144.27 million
Profitability
Miscellaneous
Employees27
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions
What is Merrimack Pharmaceuticals' stock symbol?
Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."
When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?
Merrimack Pharmaceuticals's stock reverse split on the morning of Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were Merrimack Pharmaceuticals' earnings last quarter?
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.28) by $0.05. View Merrimack Pharmaceuticals' Earnings History.
When is Merrimack Pharmaceuticals' next earnings date?
What price target have analysts set for MACK?
3 equities research analysts have issued 12 month price targets for Merrimack Pharmaceuticals' shares. Their predictions range from $4.00 to $4.00. On average, they anticipate Merrimack Pharmaceuticals' stock price to reach $4.00 in the next twelve months. This suggests that the stock has a possible downside of 40.2%. View Analyst Price Targets for Merrimack Pharmaceuticals.
What is the consensus analysts' recommendation for Merrimack Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merrimack Pharmaceuticals in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Merrimack Pharmaceuticals.
Has Merrimack Pharmaceuticals been receiving favorable news coverage?
Press coverage about MACK stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Merrimack Pharmaceuticals earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are some of Merrimack Pharmaceuticals' key competitors?
Some companies that are related to Merrimack Pharmaceuticals include Aptorum Group (APM), OptiNose (OPTN), BioDelivery Sciences International (BDSI), Sinovac Biotech (SVA), Kadmon (KDMN), Albireo Pharma (ALBO), MediciNova (MNOV), Urovant Sciences (UROV), Kezar Life Sciences (KZR), Keryx Biopharmaceuticals (KERX), Kindred Biosciences (KIN), Geron (GERN), Karyopharm Therapeutics (KPTI), Osmotica Pharmaceuticals (OSMT) and Insys Therapeutics (INSY).
What other stocks do shareholders of Merrimack Pharmaceuticals own?
Who are Merrimack Pharmaceuticals' key executives?
Merrimack Pharmaceuticals' management team includes the folowing people:
- Dr. Richard Peters, Pres, CEO & Director (Age 56)
- Ms. Jean M. Franchi, CFO & Treasurer (Age 53)
- Mr. Jeffrey A. Munsie, Gen. Counsel, Head of Corp. Operations & Sec. (Age 42)
- Dr. Daryl C. Drummond Ph.D., Head of Research (Age 50)
- Dr. Sergio L. Santillana, Chief Medical Officer (Age 56)
Who are Merrimack Pharmaceuticals' major shareholders?
Merrimack Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include 22NW LP (5.62%), Dimensional Fund Advisors LP (4.28%), Dimensional Fund Advisors LP (4.28%), BlackRock Inc. (1.92%), Connor Clark & Lunn Investment Management Ltd. (1.27%) and Two Sigma Investments LP (0.55%). Company insiders that own Merrimack Pharmaceuticals stock include Daryl C Drummond and Ulrik B Nielsen. View Institutional Ownership Trends for Merrimack Pharmaceuticals.
Which institutional investors are selling Merrimack Pharmaceuticals stock?
Which institutional investors are buying Merrimack Pharmaceuticals stock?
How do I buy shares of Merrimack Pharmaceuticals?
Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merrimack Pharmaceuticals' stock price today?
One share of MACK stock can currently be purchased for approximately $6.69.
How big of a company is Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals has a market capitalization of $89.26 million and generates $144.27 million in revenue each year. Merrimack Pharmaceuticals employs 27 workers across the globe.
What is Merrimack Pharmaceuticals' official website?
How can I contact Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]
MarketBeat Community Rating for Merrimack Pharmaceuticals (NASDAQ MACK)
MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe MACK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MACK will underperform the S&P 500 over the long term. You may vote once every thirty days.
